Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segments

此次交易强化了在领先的学术与政府以及知识产权业务板块的战略聚焦

Proceeds strengthen balance sheet and enhance financial flexibility

所得款项有助于强化资产负债表并提升财务灵活性

LONDON

伦敦

,

，

Oct. 6, 2026

2026年10月6日

/PRNewswire/ -- Clarivate Plc (NYSE:

/PRNewswire/ -- Clarivate Plc（纽约证券交易所：

CLVT

CLVT

) ('Clarivate' or the 'Company'), a leading global provider of transformative intelligence, today announced the successful completion of the sale of its Life Sciences & Healthcare segment to Altaris, LLC ('Altaris'), advancing Clarivate's transformation and simplifying its portfolio. The transaction for $600 million was previously announced on July 6, 2026..

科睿唯安（Clarivate，以下简称“科睿唯安”或“公司”）是一家全球领先的变革性情报提供商，今日宣布已成功完成将其生命科学与医疗保健业务部门出售给Altaris, LLC（以下简称“Altaris”）的交易，此举推动了科睿唯安的转型并简化了其业务组合。该笔交易金额为6亿美元，此前已于2026年7月6日宣布。

With the completion of the transaction, Clarivate is now a more-focused subscription-first global provider of trusted proprietary data and authoritative content, AI-powered intelligence solutions, embedded workflow software, and tech-enabled services. The leading Academia & Government and Intellectual Property segments benefit from the deep subject matter expertise of Clarivate colleagues and shared infrastructure to serve customers at critical moments of innovation, research, learning, and intellectual property creation and protection.

随着交易的完成，科睿唯安现已成为一家更加专注、以订阅为先的全球提供商，提供可信的专有数据与权威内容、人工智能驱动的情报解决方案、嵌入式工作流软件以及技术赋能的服务。其领先的学术与政府事务板块以及知识产权板块，得益于科睿唯安员工深厚的专业领域专长和共享的基础设施，能够在创新、研究、学习以及知识产权创造与保护的关键时刻为客户提供服务。

This helps organizations move from information overload to confident decision making. .

这有助于组织从信息过载转向自信决策。

Matti Shem Tov, Chief Executive Officer, Clarivate said: 'This is an important milestone in Clarivate's transformation journey. The successful completion of this transaction further advances our Value Creation Plan by sharpening our focus, simplifying our portfolio, and strengthening our financial profile.

科睿唯安首席执行官马蒂·谢姆·托夫表示：“这是科睿唯安转型历程中的一个重要里程碑。此次交易的顺利完成，通过聚焦核心业务、简化产品组合以及强化财务状况，进一步推动了我们的价值创造计划。”

We are now positioned as a more focused company centered on two market-leading segments with attractive recurring revenue characteristics, deep customer relationships, and significant opportunities to leverage AI-driven innovation.'.

我们现在定位为一家更加专注的公司，专注于两个市场领先的领域，这些领域具有吸引人的经常性收入特征、深厚的客户关系以及利用人工智能驱动创新的重大机遇。

'I want to thank our Life Sciences & Healthcare colleagues for their many contributions to Clarivate and wish them continued success as part of Altaris,' Shem Tov continued. 'We also thank our customers for their continued trust and partnership throughout this process.'

“我要感谢我们的生命科学与医疗健康领域的同事为科睿唯安作出的诸多贡献，并祝愿他们在加入 Altaris 后继续取得成功。” Shem Tov 表示，“我们还感谢客户在这一过程中始终给予的信任与合作。”

As previously communicated, Clarivate intends to use the transaction proceeds to reduce debt and further strengthen its balance sheet, while enhancing strategic and financial flexibility. The transaction also supports the Company's efforts to improve revenue quality, expand profitability, and increase focus on long-term value creation..

如先前所沟通，科睿唯安计划利用本次交易所得款项降低债务并进一步巩固其资产负债表，同时提升战略与财务灵活性。该交易亦有助于公司提高收入质量、扩大盈利能力，并更加专注于长期价值创造。

Michael Easton, Chief Financial Officer, Clarivate said: 'The completion of this transaction marks another meaningful step in executing our strategy. Our streamlined business model and stronger balance sheet position us well to invest in innovation, support our customers, and drive sustainable growth and shareholder value.'.

科睿唯安首席财务官迈克尔·伊斯顿表示：“此次交易的完成标志着我们在执行战略方面又迈出了有意义的一步。我们精简的业务模式和更强劲的资产负债表使我们处于有利地位，能够投资于创新、支持客户，并推动可持续增长和股东价值。”

The Company will report its third quarter 2026 financial results on Tuesday, November 3, 2026, and will update its full year 2026 guidance to reflect the divestiture of the Life Sciences & Healthcare segment.

公司将于2026年11月3日（星期二）公布其2026年第三季度财务业绩，并更新其2026年全年指引，以反映生命科学与医疗保健部门的剥离。

A more focused Clarivate

更加聚焦的科睿唯安

Following the divestiture, Clarivate's portfolio consists of:

剥离完成后，科睿唯安的产品组合包括：

Academia & Government

学术界与政府

Providing trusted intelligence, workflow solutions, and services that help universities, research institutions, libraries, governments, and funders accelerate research, advance learning, and improve outcomes. Home to leading research, education and library solutions, including Web of Science, ProQuest, Alma and Vega..

提供值得信赖的情报、工作流解决方案及服务，助力高校、科研机构、图书馆、政府和资助方加速研究进程、推动学习进步并提升成果。旗下汇聚领先的研究、教育和图书馆解决方案，包括 Web of Science、ProQuest、Alma 和 Vega。

Intellectual Property

知识产权

Delivering leading patent, trademark, brand protection, and innovation intelligence solutions that help organizations create, protect, and commercialize intellectual property. Home to IPOne, Derwent, CompuMark, IPfolio and other leading IP solutions.

提供领先的专利、商标、品牌保护和创新情报解决方案，帮助组织创造、保护并商业化知识产权。旗下拥有 IPOne、Derwent、CompuMark、IPfolio 等领先的知识产权解决方案。

Together, these businesses are underpinned by proprietary content, workflow software, and expanding AI capabilities that help customers make faster, more informed decisions.

这些业务共同依托专有内容、工作流软件以及不断扩展的人工智能能力，帮助客户做出更快速、更明智的决策。

Forward-looking statements

前瞻性陈述

This release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, 'forward-looking statements' within the meaning of the 'safe harbor provisions' of the Private Securities Litigation Reform Act of 1995.

本次发布包含表达我们对未来事件或未来结果的意见、预期、信念、计划、目标、假设或预测的陈述，因此这些陈述属于或可能被视为1995年《私人证券诉讼改革法》“安全港条款”意义上的“前瞻性陈述”。

These forward-looking statements include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, the divestiture of our Life Sciences & Healthcare business or any other strategic transactions we may explore, the anticipated use of proceeds from the divestiture of our Life Sciences & Healthcare business, any anticipated cost savings or other benefits as a result of the divestiture of our Life Sciences & Healthcare business, our financial guidance for the fiscal year 2026, key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan, our growth strategies and future business prospects, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence on our business and strategy, and the timing of any of the foregoing.

这些前瞻性陈述包括所有非历史事实的事项，包括涉及以下内容的陈述：我们关于剥离生命科学与医疗保健业务或我们可能探索的任何其他战略交易的意图、信念或当前预期；剥离生命科学与医疗保健业务所得款项的预期用途；因剥离生命科学与医疗保健业务而预期的任何成本节约或其他利益；我们对2026财年的财务指引、其主要驱动因素及基本假设；我们的价值创造计划的影响或预期效益；我们的增长战略和未来业务前景；全球宏观经济的不确定性和波动性；人工智能对我们的业务和战略的影响；以及前述各项的时间安排。

These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms 'believes,' 'estimates,' 'anticipates,' 'expects,' 'seeks,' 'projects,' 'intends,' 'plans,' 'may,' 'will,' or 'should' or, in each case, their negative or other variations or comparable terminology.

这些前瞻性陈述通常可以通过使用前瞻性术语来识别，包括“相信”、“估计”、“预期”、“期望”、“寻求”、“预测”、“打算”、“计划”、“可能”、“将”或“应当”等词语，或在各种情况下的其否定形式、其他变体或类似术语。

Such forward-looking statements are based on available current market material and management's expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number o.

此类前瞻性陈述基于当前可获得的市场资料以及管理层对影响我们的未来事件的预期、信念和预测。这些前瞻性陈述涉及诸多

www.clarivate.com

www.clarivate.com

.

。

About Clarivate

关于科睿唯安

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government and Intellectual Property. For more information, please visit

科睿唯安是全球领先的变革性情报提供商。我们在学术与政府事务以及知识产权领域，提供增强型数据、洞察与分析、工作流解决方案以及专家服务。欲了解更多信息，请访问

www.clarivate.com

www.clarivate.com

.

。

SOURCE Clarivate Plc

来源：科睿唯安有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，附带

Request a Demo

申请演示